The Israeli biopharmaceutical company BioLineRX Ltd announced Tuesday that it would collaborate with U.S. industry heavyweight Merck to study a group of drugs for the treatment of pancreatic cancer.
The companies will work together in a mid-stage research to appraise the safety and efficacy of the combination of BioLineRx’s BL-8040 and Merck’s Keytruda in patients inflicted with metastatic pancreatic adenocarcinoma.
Since certain tumors exhibits only a meek response to the remaining immunotherapies, officials are progressively going for clinical studies. These studies are mostly the combinations of immuno-oncology agents with other degrees of drugs, stated Kinneret Savitsky, BioLineRx’s chief executive.
BL-8040 acts against CXCR4 receptors which are tangled in tumor progression, the company informed. It has been revealed in numerous clinical trials to mobilize immune cells and to be effective at instigating direct tumor cell death.
Keytruda, an antibody, operates with the means by aggregating the capacity of the body’s immune system to help spot and battle tumor cells, stated Merck. The antibody is known as MSD outside the United States and Canada.
Pancreatic adenocarcinoma is responsible for majority cases of pancreatic cancer, says the American Cancer Society. Particular symptoms often do not grow until the disease spreads to an advanced stage, which is revealed in a low five-year survival rate.
The study is scheduled to begin by mid-2016 and both companies will have the selection to enlarge the collaboration to embrace a pivotal registration study, BioLineRX stated.
After listening to Merck’s presentation, it’s apparent that the company holds a well-laid plan to cultivate over the long run. The immuno-oncology platform with its diverse portfolio of diabetes products and vaccines bids for growth stability and pricing power that could profit shareholders for years to come.
The important questions are whether the drugs will be able to play in very competitive landscapes (i.e., oncology and HCV), and if its acquisitions will remunerate dividends as hoped. Although the answers to these questions are yet to answer, investors who are ready to hold for the long-term should be compensated by a company with an above-average dividend yield and robust cash flow.
Steve Smith
Latest posts by Steve Smith (see all)
- Merck & Co Inc, collaborates with BioLineRX to research drug combo in the battle of pancreatic cancer - January 13, 2016
- Royal Dutch Shell Plc and BP Plc must continue their dividends of 7.7% and 7.3% - January 12, 2016
- Health Care stocks with their development prescriptions for the year 2016 - January 12, 2016
